Proprietary nasal delivery formulation of diazepam reaches NDA7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.
A proprietary nasal delivery formulation of diazepam for the treatment of epilepsy developed by CDMO, Particle Sciences, a Lubrizol LifeSciences company, has been submitted as a New Drug Application (NDA) to the FDA by San-Diego-based Neurelis.
Valtoco, previously referred to in clinical development as ‘NRL-1’, is the lead product candidate of Neurelis, which worked closely with Particle Sciences on the formulation of the diazepam nasal spray designed to treat acute repetitive seizures in patients over the age of six.
Using its Dose platform that combines empirically obtained data with customized solubility software based on Hansen solubility parameters, Particle Sciences was able to achieve extremely high levels of solubilized diazepam using a benign vehicle that is compatible with nasal delivery. The resulting absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial of healthy volunteers.
The NDA for Valtoco is a 505(b)(2) filing utilizing rectal diazepam gel, the only currently FDA approved therapeutic product for home treatment of acute repetitive seizures, as the Reference Listed Drug. The NDA is supported by further extensive clinical studies in healthy volunteers and patients with epilepsy, with more than 1,600 seizures treated to date with the nasal spray.
Dr Robert Lee, president of Particle Sciences said: “It’s rewarding to see Valtoco reach this key milestone after Neurelis’ successful clinical trials. This product will bring positive improvements to the lives of many patients with acute repetitive seizures”.
Lee added: “Nasal delivery is often an overlooked route of administration, but it can offer an ideal route and increase bioavailability for several drug types, particularly those designed to treat diseases of the central nervous system. We are seeing real growth in this area and expect to see an increase in demand for nasal formulations in the future as we continue to focus on the development of complex drug products.”
Craig Chambliss, President and CEO of Neurelis said: “Having assessed dozens of formulation approaches for solving the challenges with delivering intranasal benzodiazepines for epilepsy patients, we partnered with Particle Sciences to leverage their experience and expertise in solving for a formulation issue that has kept poorly soluble drugs from being developed for significant unmet clinical needs.”
'Tamper-evident' benefits are evident
28 Feb 2019
2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.Read more
All Recipharm facilities ready for EU serialisation, regardless of Brexit
15 Feb 2019
The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.Read more
Brexit - the EU FMD's painful problem
7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.Read more
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
27 Jan 2019
New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.Read more
New API screening program strengthens Particle Sciences' nanomilling offering
22 Jan 2019
Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.Read more
Univercells introduces breakthrough vaccine manufacturing platform
13 Jan 2019
The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.Read more
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
One month on: medical cannabis is still taboo despite change in law
11 Dec 2018
Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.Read more
EU FMD - time is running out!
13 Nov 2018
Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation